Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Advanced Cancers: early-phase trial registry

1 of 11 indexed Advanced Cancers trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,577 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

11 US clinical trials · 1 currently recruiting · #1,577 of 28,707 conditions by registered trial count

Advanced Cancers: 11 US clinical trials tracked, 1 recruiting.

Advanced Cancers is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 10 of these trials.

Enrollment posture brief

Registry condition advanced-cancers

OPEN 1 | RECR 9% | LATE 1 | EARLY 9 | RANK #1577 | SPON 10

Volume-matched condition peers

Nearest open-share peer: Brain Tumors (9% recruiting · 11 trials)

Acute Pancreatitis81.8%Acute Stroke45.5%Acquired Brain Injury36.4%Acute Lung Injury9.1%Advanced Cancers (this)9%
Open-enrollment share among volume-matched conditions near Advanced Cancers

Advanced Cancers lists 1 open slots (9% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Advanced Cancers on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Advanced Cancers is recruiting below its size-band peers.

    1 of 11 indexed trials (9.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Advanced Cancers research.

    M.D. Anderson Cancer Center accounts for 10 of 11 trials (90.9%). 2 distinct sponsors appear on at least one study for this condition label.

  3. Most Advanced Cancers trials plan to enrol fewer than 100 people.

    Median target enrolment is 52 among the 11 trials that report a genuine target (sentinel values excluded). 9 of those (81.8%) plan for fewer than 100 participants.

  4. Advanced Cancers research is mostly interventional.

    10 interventional and 1 observational studies make up this index (90.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 16Phase 23Phase 41

Open and recent trials

11 total, page 1 of 1

RECRUITING Phase 2 15 participants

Psilocybin in Cancer Pain Study

Yvan Beaussant, MD, MSci

NCT06001749
ACTIVE NOT RECRUITING Phase 1 165 participants

The Effects of Ginseng on Cancer-Related Fatigue

M.D. Anderson Cancer Center

NCT01375114
ACTIVE NOT RECRUITING Phase 2 93 participants

Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer

M.D. Anderson Cancer Center

NCT01949662
ACTIVE NOT RECRUITING Phase 1 28 participants

Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies

M.D. Anderson Cancer Center

NCT02668770
COMPLETED Phase 1 143 participants

Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer

M.D. Anderson Cancer Center

NCT01266057
COMPLETED Phase 1 68 participants

MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies

M.D. Anderson Cancer Center

NCT02042989
COMPLETED Phase 1 61 participants

Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma

M.D. Anderson Cancer Center

NCT01983969
COMPLETED Phase 4 52 participants

Tolvaptan in Hyponatremic Cancer Patients

M.D. Anderson Cancer Center

NCT01199198
COMPLETED Phase 2 32 participants

The Effects of Thalidomide on Symptom Clusters

M.D. Anderson Cancer Center

NCT00379353
COMPLETED Phase 1 21 participants

Study of Vemurafenib, Carboplatin, and Paclitaxel

M.D. Anderson Cancer Center

NCT01636622
COMPLETED 20 participants

Patient-Reported Outcomes Version of Common Terminology Criteria (CTCPRO) Cognitive Debriefing

M.D. Anderson Cancer Center

NCT00909207

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 3
Phase 4 1

Top Sponsors

M.D. Anderson Cancer Center 10 trials
Yvan Beaussant, MD, MSci 1 trials

Named interventions

Most-linked intervention names on Advanced Cancers records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Vorinostat Drug
3 trials
Placebo Drug
3 trials
Questionnaires Behavioral
2 trials
Tolvaptan Drug
1 trials
MLN9708 Drug
1 trials
Panax Ginseng Drug
1 trials
MGN1703 Drug
1 trials
Haloperidol decanoate Drug
1 trials

US sites by state

Facility locations filed on Advanced Cancers trials. A trial with sites in several states counts in each.

Texas 10 trials
Massachusetts 2 trials
New York 1 trials
North Carolina 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Advanced Cancers page

11 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced Cancers condition card totals 11 registered trials; most-linked intervention Vorinostat; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.